| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial M Kudo, RS Finn, S Qin, KH Han, K Ikeda, F Piscaglia, A Baron, JW Park, ... The Lancet 391 (10126), 1163-1173, 2018 | 4394 | 2018 |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2103 | 2018 |
| BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update M Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ... Journal of hepatology 76 (3), 681-693, 2022 | 1878 | 2022 |
| Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ... The Lancet Oncology 21 (5), 671-684, 2020 | 1171 | 2020 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of oncology 29, iv238-iv255, 2018 | 864 | 2018 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 771 | 2021 |
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial AX Zhu, M Kudo, E Assenat, S Cattan, YK Kang, HY Lim, RTP Poon, ... Jama 312 (1), 57-67, 2014 | 647 | 2014 |
| A comparison of fibrosis progression in chronic liver diseases T Poynard, P Mathurin, CL Lai, D Guyader, R Poupon, MH Tainturier, ... Journal of hepatology 38 (3), 257-265, 2003 | 608 | 2003 |
| Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ F Lordick, F Carneiro, S Cascinu, T Fleitas, K Haustermans, G Piessen, ... Annals of Oncology 33 (10), 1005-1020, 2022 | 443 | 2022 |
| Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer DY Oh, A Ruth He, S Qin, LT Chen, T Okusaka, A Vogel, JW Kim, ... NEJM evidence 1 (8), EVIDoa2200015, 2022 | 386 | 2022 |
| Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis A Vogel, CP Strassburg, MP Manns Hepatology 35 (1), 126-131, 2002 | 311 | 2002 |
| Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients S Berhane, H Toyoda, T Tada, T Kumada, C Kagebayashi, S Satomura, ... Clinical Gastroenterology and Hepatology 14 (6), 875-886. e6, 2016 | 274 | 2016 |
| Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines A Vogel, E Martinelli, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, ... Annals of Oncology 32 (6), 801-805, 2021 | 264 | 2021 |
| Correction to:“Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up” A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of Oncology 30 (5), 871-873, 2019 | 257 | 2019 |
| Autoimmune hepatitis, from mechanisms to therapy MP Manns, A Vogel Hepatology 43 (S1), S132-S144, 2006 | 250 | 2006 |
| GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis J Best, LP Bechmann, JP Sowa, S Sydor, A Dechêne, K Pflanz, S Bedreli, ... Clinical gastroenterology and hepatology 18 (3), 728-735. e4, 2020 | 219 | 2020 |
| Nuclear factor-eythroid 2–related factor 2 prevents alcohol-induced fulminant liver injury J Lamlé, S Marhenke, J Borlak, R Von Wasielewski, CJP Eriksson, ... Gastroenterology 134 (4), 1159-1168. e2, 2008 | 219 | 2008 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 207 | 2023 |
| Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP‐glucuronosyltransferase UGT1A4 U Ehmer, A Vogel, JK Schütte, B Krone, MP Manns, CP Strassburg Hepatology 39 (4), 970-977, 2004 | 201 | 2004 |
| Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ R Obermannová, M Alsina, A Cervantes, T Leong, F Lordick, M Nilsson, ... Annals of Oncology 33 (10), 992-1004, 2022 | 197 | 2022 |
Michael MannsMedizinische Hochschule HannoverVerified email at mh-hannover.de
